SCHEMBL24026469

SCHEMBL24026469

CCc1cccc(-c2cccnn2)c1OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYK2 P29597 2/20 0.39
HTR2C P28335 6/20 0.37
HTR2A P28223 2/20 0.37
HTR2B P41595 1/20 0.36
CASP6 P55212 1/20 0.34
ADRA2A P08913 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33
ABL1 P00519 1/20 0.33
P2RX7 Q99572 1/20 0.33
CTDSP1 Q9GZU7 1/20 0.33
GRM5 P41594 1/20 0.32
DRD2 P14416 1/20 0.32
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
NOS3 P29474 1/20 0.32
NOS1 P29475 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
GABRA1 P14867 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17194922 0.80 TLR8 (0.40) TYK2HTR2CHTR2AHTR2BP2RX7
SCHEMBL7869431 0.80 HTR2C (0.39) HTR2CHTR2AHTR2BCASP6CTDSP1
SCHEMBL30622218 0.78 KDM4E (0.48) TYK2HTR2CHTR2AHTR2BP2RX7
SCHEMBL29132971 0.78 KDM4E (0.48) TYK2HTR2CHTR2AHTR2BP2RX7
SCHEMBL20155915 0.77 TYK2 (0.35) TYK2HTR2CHTR2AHTR2BABL1
SCHEMBL20155993 0.76 ADRA2A (0.33) ADRA2AADRA2BADRA2CP2RX7DRD2
SCHEMBL18415070 0.76 TYK2 (0.37) TYK2HTR2CHTR2AHTR2BALDH1A1
SCHEMBL20150102 0.76 TYK2 (0.37) TYK2HTR2CHTR2AHTR2BALDH1A1
SCHEMBL20230885 0.76 TYK2 (0.46) TYK2HTR2CHTR2AHTR2BCASP6
SCHEMBL17198826 0.75 CCNT1 (0.40) TYK2CASP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11220508-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2022-01-11 US disclosed
US-11174265-B2 2021-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11220508-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 TYK2 1/4885HTR2C 3262/4885HTR2A 3475/4885
US-11174265-B2 TYK2, JAK2, JAK1 TYK2 1/4885HTR2C 2864/4885HTR2A 3149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.